CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...
Pfizer announces positive results from TALAPRO-3 study of Talzenna plus Xtandi in metastatic prostate cancer: New York Tuesday, June 2, 2026, 18:00 Hrs [IST] Pfizer Inc. announced ...
MedPage Today on MSN
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...
ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...
Minghui Pharmaceutical ('Minghui'), a late-stage clinical biopharmaceutical company focused on developing innovative ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...
MedPage Today on MSN
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...
(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results